Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2014—Pall Life Sciences’ Acrodisc WBC premium syringe filter is a filtration device designed specifically for use in the capture and recovery of leukocytes and the separation of red blood cells. The Acrodisc WBC filter contains the company’s patented Leukosorb media.
September 2014—Eco-Tek products by Kem-En-Tec, distributed in the U.S. by Rainbow Scientific, reduce the environmental impact of ELISA, blotting, or immunohistochemistry applications by eliminating biological and chemical hazards commonly found in diagnostic assay components, including bovine serum albumin, sodium azide, and harmful organic solvents, without compromising quality, reliability, or stability.
September 2014—Diagnostica Stago celebrated the success of its newest instrument line with the competitive conversion placement of its 100th Compact Max in six months. The Compact Max, an intelligent, user-friendly platform for coagulation testing, is the first of the Max line of instruments that will be rolling out to laboratories worldwide over the next couple of years.
September 2014—The Mix&Go product is a proprietary surface coating for use in diagnostic testing from Anteo Diagnostics. Mix&Go incorporates a type of molecular Velcro that provides a novel approach for attaching fragile proteins to synthetic surfaces distinct to the traditional methods, enabling the development of sensitive and affordable diagnostics.
September 2014—The promises and perils of big data and mobile health were among the hot topics at this year’s meeting of the American Association for Clinical Chemistry.
August 2014—Bio-Rad Laboratories has extended its contract with Premier, a U.S.-based group purchasing organization. The agreement includes Premier general level and ASCEND members.
August 2014—A Proteinase–3 (cANCA) native autoantigen for the in vitro diagnostics market is available from The Binding Site. Expressly designed for use as an integral component in solid-phase, ELISA-based immunoassay test procedures, the Proteinase–3 (cANCA) native autoantigen is for clinical and life-science researchers, medical laboratory professionals, and manufacturers of in vitro diagnostic immunoassay kits and tests for autoimmune conditions.
August 2014—MALDI Biotyper systems can be configured for further functionality by adding new or expanded research-use only software modules or hardware accessories.
The MBT Explorer module provides multiple bioinformatics approaches for spectra comparison, statistical data interpretation, and the generation of customer-specific reference library entries (main spectra) of strains of special interest. Such sub-libraries can be exported and re-imported in networks of collaborating labs.
August 2014—Inova Diagnostics announced the global launch of Quanta Lite Calprotectin, an FDA-cleared, quantitative ELISA that detects calprotectin levels, aids in the diagnosis of inflammatory bowel disease, and can also help differentiate, in conjunction with other laboratory and clinical findings, IBD from irritable bowel syndrome.
August 2014—Biocare Medical was issued a patent from the U.S. Patent and Trademark Office for its PIN-4 (CK5/14 + P63 + P504S) multiplex immunohistochemistry technology.
